We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.14 | 2.10 | 2.18 | 2.20 | 2.19 | 2.19 | 604,698 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/12/2017 09:18 | Market cap still a miserly £215m..... That would be about right for the pipeline EXCLUDING Lupuzor IMO. DYOR etc. | qazwsxedc69 | |
11/12/2017 09:17 | going very nicely indeed.... | qs99 | |
11/12/2017 09:04 | indeed...£2 and beyond looks very doable at this rate IMO...DYOR | qs99 | |
11/12/2017 09:02 | they can't keep up with demand | adejuk | |
11/12/2017 09:02 | £1.60 Gone! | spmc | |
11/12/2017 08:54 | I agree with Ham.. The spread seems to be quite wide on this one and with an upwards trend it might cost a fair bit to buy back. I bought some VELA this morning (actually lodged it over the weekend) and ended up paying 15% above because of the spread. | tricky red | |
11/12/2017 08:50 | Yep, if you try profit taking and re-entry on this share, you are going to get caught out. This share is more gappy than Terry Thomas' front teeth (god rest is wonderful soul) | hamhamham1 | |
11/12/2017 08:50 | The risk reward here is unbelievable. I've only taken a small stake but this is surely a share everyone should have a nibble from. | mad foetus | |
11/12/2017 08:46 | I had a target of £2.50-£5 | divinessence | |
11/12/2017 08:37 | Grabbed a few more. IMM is the one to be in. | top tips | |
11/12/2017 08:26 | Have you been topping up top tips? LOL | flavio_monteiro | |
11/12/2017 08:19 | This is just the start. Its worth billions. | top tips | |
11/12/2017 08:19 | I'm not selling any NYBoy for a long while don't worry. This is a hold extremely tight for me. | spawny100 | |
11/12/2017 08:18 | With most now completed the trial.looks like it could be good news next quarter | fidra | |
11/12/2017 08:17 | Just hold until next Spring for substantive returns imho Starting to warm up now on a cold blighty day. | ny boy | |
11/12/2017 08:12 | Volume started out with a bang this morning | spawny100 | |
11/12/2017 08:11 | Only dear the day you buy it :-) | che7win | |
11/12/2017 08:08 | Bit perky this morning for a dark damp cold Monday | spawny100 | |
11/12/2017 08:04 | 175p next target | herschel k | |
10/12/2017 22:25 | Edit: Majority of the patients showed resolution of the arthritis measure (4 point score). | money maker1 | |
10/12/2017 22:23 | An analyst said they understood the arthritis measures were "completely resolved" in the Phase 2b Lupuzor trial. | money maker1 | |
10/12/2017 21:32 | No problem Jpl, I was very excited when Tim said that! Well the SLEDAI2k they are using measures arthritis as a symptom of lupus, and in the phase IIb trial there was 'promising' results on the arthritis measure indicating it could be used for that. I can't remember ever finding the exact results of the arthritis measure in phase IIb, not sure if it was ever shared. The asthma results from p140 were very strong in mice! And mice share 97.5% of their DNA with humans, so surely that's as good as a phase II trial ;) | asat91 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions